Nautilus Biotechnology Inc
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Exchange Act the Registrant has duly caused this Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| NAUTILUS BIOTECHNOLOGY, INC. | |
|---|---|
| By: | /s/ Sujal Patel |
| Sujal Patel | |
| Chief Executive Officer | |
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Sujal Patel and Anna Mowry, and each of them, as his or her true and lawful attorney-in-fact and agent with full power of substitution, for him or her in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact, proxy and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact, proxy and agent, or his or her substitute, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed by the following persons in the capacities and on the dates indicated:
| Signature | Title | Date |
|---|---|---|
| /s/ Sujal Patel | Chief Executive Officer, President and Director | February 27, 2025 |
| Sujal Patel | (Principal Executive Officer) | |
| /s/ Anna Mowry | Chief Financial Officer | February 27, 2025 |
| Anna Mowry | (Principal Financial and Accounting Officer) | |
| /s/ Michael Altman | Director | February 27, 2025 |
| Michael Altman | ||
| /s/ Melissa Epperly | Director | February 27, 2025 |
| Melissa Epperly | ||
| /s/ Parag Mallick | Director | February 27, 2025 |
| Parag Mallick | ||
| /s/ Matthew McIlwain | Director | February 27, 2025 |
| Matthew McIlwain | ||
| /s/ Farzad Nazem | Director | February 27, 2025 |
| Farzad Nazem | ||
| /s/ Vijay Pande | Director | February 27, 2025 |
| Vijay Pande | ||
| /s/ Matthew L. Posard | Director | February 27, 2025 |
| Matthew L. Posard | ||
| /s/ Karen Akinsanya | Director | February 27, 2025 |
| Karen Akinsanya | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.